AVEO PHARMACEUTICALS INC(NASDAQ:AVEO) stock News

AVEO Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: AVEO Pharmaceuticals, Inc.

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

a year ago - By: AVEO Pharmaceuticals, Inc.

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

a year ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

a year ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

2 years ago - By: AVEO Pharmaceuticals, Inc.

LG Chem Completes Acquisition of AVEO Oncology

3 years ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Stockholders Approve Acquisition by LG Chem

a year ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

a year ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

2 years ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

2 years ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

3 years ago - By: Seeking Alpha

Aveo Oncology shareholders approve acquisition by LG Chem (NASDAQ:AVEO)

3 years ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

3 years ago - By: Benzinga - Mentions: ACA ASML SIX IAA ...

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022

3 years ago - By: AVEO Pharmaceuticals, Inc.

AVEO Oncology Reports Third Quarter 2022 Financial Results

3 years ago - By: Benzinga - Mentions: CVX CNHI NOW DBD ...

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022

3 years ago - By: Weiss Law

SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.

3 years ago - By: Kahn Swick & Foti, LLC

AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO

3 years ago - By: InvestorPlace - Mentions: ZVO AKUS RMED

Zovio (ZVO) Stock Soars 90% Ahead of Oct. 25 Dissolution Vote

3 years ago - By: Ademi LLP

AVEO PHARMACEUTICALS INC (AVEO) Stock News

AVEO Latest News, Press Relases and Analysis

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

LG Chem Completes Acquisition of AVEO Oncology

AVEO Oncology Stockholders Approve Acquisition by LG Chem

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Aveo Oncology shareholders approve acquisition by LG Chem (NASDAQ:AVEO)

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022

AVEO Oncology Reports Third Quarter 2022 Financial Results

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022

SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.

AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO

Zovio (ZVO) Stock Soars 90% Ahead of Oct. 25 Dissolution Vote

Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem